BONESUPPORT(TM) announced that due to internal delays at the U.S. Food and Drug Administration (FDA), the agency has informed BONESUPPORT that a response to the company's De Novo application for marketing authorization for the antibiotic eluting product CERAMENT G for the indication osteomyelitis (bone infection) will be delayed with a few weeks.